This growth is fueled by increasing prevalence rates of autoimmune diseases like rheumatoid arthritis and psoriasis, advancements in targeted therapies, and rising R&D investments in next-generation inhibitors. According to the Global Burden of Disease Study, the incidence of autoimmune conditions has risen globally, with rheumatoid arthritis affecting approximately 14 million people in 2023. This trend highlights the increasing recognition and diagnosis of such conditions, fueled by advancements in medical diagnostics and growing awareness among healthcare providers.
